These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10425308)

  • 1. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.
    Ellerhorst JA; Bedikian A; Ring S; Buzaid AC; Eton O; Legha SS
    Oncol Rep; 1999; 6(5):1097-9. PubMed ID: 10425308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.
    Hubert A; Lyass O; Pode D; Gabizon A
    Anticancer Drugs; 2000 Feb; 11(2):123-7. PubMed ID: 10789595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer.
    Skubitz KM
    Invest New Drugs; 2002 Feb; 20(1):101-4. PubMed ID: 12003184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.
    Skubitz KM
    Cancer Invest; 2002; 20(5-6):693-9. PubMed ID: 12197225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
    Lotem M; Hubert A; Lyass O; Goldenhersh MA; Ingber A; Peretz T; Gabizon A
    Arch Dermatol; 2000 Dec; 136(12):1475-80. PubMed ID: 11115157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment.
    Vorobiof DA; Rapoport BL; Mahomed R; Karime M
    Melanoma Res; 2003 Apr; 13(2):201-3. PubMed ID: 12690306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.
    Fink W; Zimpfer-Rechner C; Thoelke A; Figl R; Kaatz M; Ugurel S; Schadendorf D
    Onkologie; 2004 Dec; 27(6):540-4. PubMed ID: 15591712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
    Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
    J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
    El-Rayes BF; Ibrahim D; Shields AF; LoRusso PM; Zalupski MM; Philip PA
    Invest New Drugs; 2005 Jan; 23(1):57-62. PubMed ID: 15528981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.
    Alvarez Secord A; Jones EL; Hahn CA; Petros WP; Yu D; Havrilesky LJ; Soper JT; Berchuck A; Spasojevic I; Clarke-Pearson DL; Prosnitz LR; Dewhirst MW
    Int J Hyperthermia; 2005 Jun; 21(4):333-47. PubMed ID: 16019859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
    Safra T; Muggia F; Jeffers S; Tsao-Wei DD; Groshen S; Lyass O; Henderson R; Berry G; Gabizon A
    Ann Oncol; 2000 Aug; 11(8):1029-33. PubMed ID: 11038041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
    Tsimberidou AM; Moulder S; Fu S; Wen S; Naing A; Bedikian AY; Daring S; Uehara C; Ng C; Wallace M; Camacho L; Kurzrock R
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1087-93. PubMed ID: 20204368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
    Muggia FM; Blessing JA; Sorosky J; Reid GC
    J Clin Oncol; 2002 May; 20(9):2360-4. PubMed ID: 11981008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.